6th Sep 2005 07:01
Sinclair Pharma PLC06 September 2005 SINCLAIR PHARMA PLC SINCLAIR LAUNCHES ATOPICLAIR(TM) IN ITALY FIRST LAUNCH IN THE EU FOLLOWING US LAUNCH IN JUNE Godalming UK, 6 September, 2005: Sinclair Pharma plc ("Sinclair" - SPH.L), thespecialty pharmaceuticals company, announces that its wholly owned Italiansubsidiary Sinclair Srl (formerly Euroderm) has launched Atopiclair(TM) foratopic dermatitis (eczema) in Italy. The launch of Atopiclair(TM) in Italy follows the product's US launch last Juneand marks an important milestone for the product. Sinclair's first productlaunch through its own sales force represents a significant step in theevolution of the Company's distribution strategy which, up to now, has been toappoint licensing partners to commercialise its products. Dr Michael Flynn, Chief Executive of Sinclair said: "Atopiclair(TM) is thefirst of our growing portfolio of approved products that we will sell directlyin Italy. The launch today of a key product through our own sales forcerepresents an important milestone for Sinclair. It gives us greater controlover our product and will lead to a substantially improved margin for theproduct. Establishment of our own sales and marketing capability in other majormarkets is an important part of our strategy going forward." Enquiries: Sinclair Pharma plcDr Michael Flynn, CEO Tel: 01483 426 6444John Barrington-Carver (Corporate PR) Tel: 07831 655 630 Financial DynamicsBen Atwell or Lucy Briggs Tel: 0207 831 3113 www.sinclairpharma.com Notes to editors: Sinclair Pharma plc based in Godalming in the UK, is quoted on the AlternativeInvestment Market (AIM) on the London Stock Exchange and has focused on theacquisition and development of niche patented pharmaceutical products in thefields of oral health, oncology support and dermatology, and bringing them tothe international market place via out-licensing partners. The Company combinesproduct evaluation, product development, regulatory and business developmentexpertise to add value to its acquired and in-house developed products. A keyelement of the Sinclair business model is to minimise risk and exposure byavoiding involvement in lengthy R&D programmes and rapidly achieving globaldistribution through a network of marketing partners. The Company has alreadylicensed its products for distribution in over 40 countries around the world. Positive Atopiclair(TM) US Study The study, conducted in 216 adult patients in the USA, demonstrated significantclinical benefits with Atopiclair(TM), when compared to a vehicle cream controlgroup. The primary endpoint was the EASI score which is a standard method ofassessment of the severity and extent of atopic dermatitis. Compared with thecontrol group Atopiclair already showed a highly significant improvement of theEASI score within the first 8 days of this 50 day trial which was maintainedthroughout the trial. Similar benefits were observed for itch, erythema, area ofatopic dermatitis, physicians global assessment, patients' preferences and theneed for rescue medication when 5.5% of patients receiving Atopiclair(TM) neededrescue medication because of disease flare up versus 40% of patients receivingthe vehicle control. Atopiclair(TM) was well tolerated with no significant sideeffects reported. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Sinclair Pharma